• Report Adverse Event or Product Quality Complaint
  • US Site
  • Global Site
AstraZeneca Medical Information
  • Therapy Areas
    • All Therapeutic Areas
    • Cardiovascular
    • Immunology
    • Infection
    • Metabolic
    • Oncology
    • Renal
    • Respiratory
    • Rare Disease (Alexion)
  • Medications
  • Resources
    • Congress Library
    • Disease Education
    • Pipeline
    • Clinical Trials
    • Open innovation
    • Access 360
    • Affordability Programs
    • Sample Closet
    • Medical Education Grant
    • Rare Disease (Alexion)
  • Connect
    • Connect with Us
    • Find an MSL
    • Request an MSL
    • Submit an MIR
    • Give Feedback
User
  • Login to My AZmedical
  • Register for My AZmedical

Search Medical Information

American Association for Cancer Research (AACR) 2021

April 10 - 15, 2021

  1. Acalabrutinib
  2. Acalabrutinib + Capivasertib (AZD5363)
  3. AZD5305
  4. Durvalumab
  5. Osimertinib + Savolitinib (AZD6094)
  6. Trastuzumab Deruxtecan (DS-8201)

Pdf

A novel circulating tumor DNA (ctDNA) assay enables monitoring of disease progression and treatment response in disseminated preclinical hematologic cancer models

Pdf

Combination activity of acalabrutinib (BTKi) and capivasertib (AKTi) in diffuse large B-cell lymphoma

Pdf

Discovery and first structural disclosure of AZD5305, a next generation, highly selective PARP1 inhibitor and trapper

Pdf

In vitro cellular profiling of AZD5305, novel PARP1-selective inhibitor and trapper

Pdf

Structure-based and property-based drug design of AZD5305, a highly selective PARP1 inhibitor and trapper

Pdf

The novel PARP1-selective inhibitor, AZD5305, is efficacious as monotherapy and in combination with standard of care chemotherapy in the in vivo preclinical models

Pdf

The novel PARP1-selective inhibitor AZD5305 has reduced haematological toxicity when compared to PARP1/2 inhibitors in pre-clinical models

Html

Phase I Dose Escalation Study of Radiotherapy and Durvalumab (MEDI4736) in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL): The RaDD Study

Html

Acquired resistance in patients with EGFRm NSCLC following treatment with osimertinib plus savolitinib in the Ph1b TATTON study Parts B and D

Html

Tumor response and MET-detection methods: exploratory biomarker analysis of Part B of the Phase 1b TATTON study

Html

Pooled Analysis of Drug-Related Interstitial Lung Disease in 8 Single-Arm Trastuzumab Deruxtecan Studies

Need Help?

Contact Us

Find an MSL

Chat with a Medical Affairs Associate

Send MIR

Submit a Medical Information Request

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. Med Co has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

Welcome to AstraZeneca
Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.

Are you a healthcare professional practicing in the United States?

I am an AstraZeneca authorized person   What is an AstraZeneca authorized person?This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca personnel. AstraZeneca US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. US Field Sales personnel should not access or browse this site. None of the content of this site should be directly linked or distributed without approval.
I am a payer or formulary decision-maker
I am neither (take me to AstraZeneca.com)
AstraZeneca Logo
Pharma Logo

This site is intended for healthcare professionals practicing in the US.

©2022 AstraZeneca. All rights reserved.

US-69609

Last Updated 11/22

Contact Us

About Us

AstraZeneca-US.com

Grant Opportunities

Survey Feedback

Your Privacy Choices

Privacy Notice

Legal Notice

Cookie Notice

US Site

Global Site

Report Adverse Event or Product Quality Complaint

Pharma Logo

Privacy NoticeLegal NoticeCookie Notice